Posted by Michael Wonder on 07 Jun 2020
Lilly bags expanded EU approval for Taltz
5 June 2020 - The European Medicines Agency has expanded the reach of Lilly's Taltz (ixekizumab) to include the treatment of adults with active ankylosing spondylitis and active non-radiographic axial spondyloarthritis.
In both cases, the approval covers patients who have not had responses to conventional therapies.
